PMOS/PCOS: Your Diagnosis Did Not Expire

PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, in May 2026. Your condition did not change that day. Your existing diagnosis did not become invalid, and the rename alone is not a reason to repeat your tests or replace a treatment that is working.

The new name matters. The old one made a complex endocrine and metabolic condition sound like a problem of ovarian cysts. The new one names what I have worked with for years: PCOS runs through your hormones and your metabolism, and what drives it differs from one woman to the next.

That is why I work by root cause: insulin-resistant, adrenal, post-pill and inflammatory. The rename does not tell you which one is yours; my free root cause quiz does, in a few minutes.

Why was PCOS renamed PMOS?

“Polycystic ovary syndrome” was inaccurate in two important ways.

First, it implied pathological ovarian cysts. The ovarian appearance associated with PCOS reflects arrested follicular development, not cyst formation. You can also have PCOS without that ovarian appearance, and ovarian morphology alone does not diagnose the condition.

Second, the name reduced a multisystem condition to one organ. PCOS can involve endocrine, metabolic, ovarian, reproductive, dermatological, and psychological features. The old name did not communicate that breadth well, and the narrow framing could contribute to confusion, stigma, delayed diagnosis, and fragmented care.

The new name came from a multistep global consensus process involving 56 academic, clinical, and patient organisations. The project gathered 14,360 new survey responses from people with PCOS and health professionals, used structured consensus workshops, and tested the scientific, cultural, and practical consequences of possible names. The result was polyendocrine metabolic ovarian syndrome (Teede et al. 2026).

The paper calls the implementation evolutionary rather than transformational. That is exactly the right frame: the language is catching up to the condition; a new condition has not appeared.

What does the new name actually say?

Polyendocrine widens the lens beyond the ovaries. PCOS is not adequately explained as a cyst problem confined to one organ.

Metabolic keeps metabolic features and long-term metabolic health inside the clinical picture. It does not mean every woman has the same degree of insulin resistance, the same body size, or the same treatment need.

Ovarian remains because ovarian dysfunction and follicular development are still part of the condition. Removing the false cyst language is not the same as declaring the ovaries irrelevant.

The name keeps the whole system in view; your own assessment shows what is happening in yours.

What did not change after the rename?

The May 2026 terminology update to the international evidence-based guideline is unusually direct: its recommendations and content remain unchanged. The clinical features, diagnostic criteria, and management approach remain unchanged too (Monash University, 2026).

For adults, diagnosis still generally requires two of three features after other causes have been excluded: irregular or absent ovulation, clinical or biochemical androgen excess, and polycystic ovarian morphology on ultrasound or elevated anti-Müllerian hormone used within the diagnostic algorithm. Adolescents require both ovulatory dysfunction and androgen excess; ultrasound and AMH are not used to diagnose PCOS in adolescence (Teede et al. 2023).

Those criteria matter if your original diagnosis was uncertain. They do not become uncertain merely because the heading on a guideline changed.

The same logic applies to treatment. If a plan is not working, causes side effects, no longer fits your goals, or was built on a weak diagnosis, that is a reason to discuss it with your clinician. So is a change in your priorities. But “PCOS now has a new name” is not, by itself, a clinical reason to stop contraception, metformin, fertility treatment, acne treatment, or anything else a qualified clinician prescribed.

When should the rename change the conversation?

Bring it up when your care has treated PCOS as nothing more than a period or fertility problem.

The name itself does not call for a blanket panel. It gives you a reason to ask whether the wider picture has been covered: “Which guideline-recommended health checks matter for me, and which are due now?” Depending on your history, that conversation may include blood pressure, cholesterol, glucose, sleep, or mental health. It may produce no new action because your current care already covers what matters. The current guideline, not the rename, is what should govern those decisions (Teede et al. 2023).

That is the difference between using the wider name as a lens and using it as a prewritten answer.

What the rename means for your root cause

The new name describes PCOS as a whole. Your root cause is what drives it in you: insulin-resistant, adrenal, post-pill or inflammatory. Many women relate to more than one; start with the one that has the biggest impact on your symptoms, because fixing it has a ripple effect on the rest.

The international guideline diagnoses PCOS by combinations of three features and does not use these four types (Teede et al. 2023). I use them because they tell each woman what to change first: the diet, the supplements and what to expect are different for each one. My free root cause quiz sorts which one you are working with, and The PCOS Repair Protocol sets out the plan for each.

Should you use PCOS or PMOS now?

Use the term that helps the other person understand you.

PCOS and PMOS are expected to coexist during a managed three-year transition. Formal work with the World Health Organization to integrate PMOS into disease-classification systems, including ICD coding, is underway. It is not already complete. The current international guideline uses PMOS alongside PCOS, and its planned 2028 update will use PMOS alone (Monash University, 2026). That 2028 guideline change is one milestone inside a wider transition, not a date on which every older record, paper, or use of PCOS suddenly becomes wrong.

That means older research, medical records, billing systems, clinician notes, support groups, and search results may continue to say PCOS. Newer papers and specialist organisations may say PMOS. When searching the evidence, I would use both terms, especially PCOS for work published before May 2026.

You do not need to correct every clinician, change every old record, or abandon a term that has helped you find care and community. “PMOS, formerly PCOS” is enough when the distinction matters.

Use the wider name to ask a better question

The rename succeeds if it stops the ovarian label from closing the case too early. The better question is not which name you use but what is driving your symptoms, and what to change first.

The new name is a better map of the territory. Your root cause is where you stand on it, and where your plan starts.